Literature DB >> 10440454

Extensive impairment of triazolam and alprazolam clearance by short-term low-dose ritonavir: the clinical dilemma of concurrent inhibition and induction.

D J Greenblatt, L L von Moltke, J P Daily, J S Harmatz, R I Shader.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10440454     DOI： 10.1097/00004714-199908000-00001

Source DB:  PubMed          Journal:  J Clin Psychopharmacol        ISSN： 0271-0749            Impact factor:   3.153


× No keyword cloud information.
  18 in total

1.  Drug Interactions with Antiretrovirals.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-06       Impact factor: 3.725

Review 2.  Drug interactions between antiretroviral drugs and comedicated agents.

Authors:  Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 3.  Drug interactions with antiretrovirals.

Authors:  Linda M Catanzaro; Judianne C Slish; Robert DiCenzo; Gene D Morse
Journal:  Curr HIV/AIDS Rep       Date:  2004-06       Impact factor: 5.071

4.  Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.

Authors:  Jan H Beumer; Venkateswaran C Pillai; Robert A Parise; Susan M Christner; Brian F Kiesel; Michelle A Rudek; Raman Venkataramanan
Journal:  Br J Clin Pharmacol       Date:  2015-09-19       Impact factor: 4.335

Review 5.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 6.  Use of antineoplastic agents in patients with cancer who have HIV/AIDS.

Authors:  Michelle A Rudek; Charles Flexner; Richard F Ambinder
Journal:  Lancet Oncol       Date:  2011-05-12       Impact factor: 41.316

7.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.

Authors:  E D Kharasch; P S Bedynek; S Park; D Whittington; A Walker; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

8.  Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.

Authors:  E D Kharasch; P S Bedynek; A Walker; D Whittington; C Hoffer
Journal:  Clin Pharmacol Ther       Date:  2008-10       Impact factor: 6.875

9.  Pharmacokinetics of phase I nevirapine metabolites following a single dose and at steady state.

Authors:  Patty Fan-Havard; Zhongfa Liu; Monidarin Chou; Yonghua Ling; Aurélie Barrail-Tran; David W Haas; Anne-Marie Taburet
Journal:  Antimicrob Agents Chemother       Date:  2013-03-04       Impact factor: 5.191

10.  Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir.

Authors:  Evan D Kharasch; Darain Mitchell; Rebecka Coles; Roberto Blanco
Journal:  Antimicrob Agents Chemother       Date:  2008-02-19       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.